The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Oxytocin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms INOSO
- 26 Feb 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 26 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated